Curative effect of empagliflozin in patients with heart failure with preserved ejection fraction without complicated by type 2 diabetes mellitus
Ma Xiangyu
Chen Yuan
Zhang Yifan
Zhao Yujie
Wang Ruimin
Chen Jian
Abstract：Objective To discuss the clinical efficacy of empagliflozin in patients with heart failure with preserved ejection fraction(HFpEF)without complicated by type 2 diabetes mellitus(T2DM).Methods HFpEF patients without complicated by T2DM(n=118)were chosen from Department of Cardiovascular Medicine in the Seventh People's Hospital of ZhengzhouCity,and divided,according to digital table,into study group(n=61)and control group(n=57).Both groups were treated with routine anti-heart failure therapy including sacubitril-valsartan,metoprolol and spironolactone,and study group was additionally given empagliflozin(10 mg/d).The patients were followed up for 6 months.The clinical efficacy was detected after treatment for 6 months.The values of left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF),maximum peak flow rate of early mitral valve diastole(Ea),and maximum peak flow rate of late mitral valve diastole(Aa)were collected from 2 groups by using Vivid7 fully digital color Doppler ultrasound diagnostic instrument before and after treatment for 1 month,3 month and 6 months.The level of high sensitivity C-reactive protein(hs-CRP)was detected by using immunoturbidimetry,N-terminal pro-brain natriuretic peptide(NT-proBNP)was detected by using ELISA,level of angiotensin Ⅱ(Ang Ⅱ)was detected by using fluorometry,scores of Minnesota Living with Heart Failure Questionnaire(MLHFQ)and 6-minute walk distance(6MWD)were detected,and re-hospitalization rate due to HF and incidence of adverse reactions were observed after treatment for 6 months.The clinical efficacy of empagliflozin was analyzed in HFpEF patients without complicated by T2DM.Results After treatment for 6 months,the total effective rate was higher(P<0.05),re-hospitalization rate due to HF was lower(P<0.05)in study group than those in control group,and incidence of adverse reactions were similar in 2 groups(P>0.05).As treatment time prolonged,LVEF,Ea and 6MWD increased(P<0.05),and Ea and 6MWD were higher in study group than those in control group(P<0.05).LVEDD,LVESD,Aa,hs-CRP,NT-proBNP,AngⅡand MLHFQ scores decreased in 2 groups,and were lower in study group than those in control group(P<0.05).Conclusion Empagliflozin can improve heart function,reduce levels of hs-CRP,NT-proBNP and AngⅡ,relieve clinical symptoms,improve life quality and exercise tolerance and reduce re-hospitalization rate due to HF with higher efficacy and safety in HFpEF patients without complicated by T2DM.
Keywords：EmpagliflozinType 2 diabetes mellitusHeart failure with preserved ejection fraction
Publication Date：2024-05-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 556-560 )